1. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. (May 2023) Authors: Cortiula, Francesco; De Ruysscher, Dirk; Steens, Michelle; Wijsman, Robin; van der Wekken, Anthonie; Alberti, Martina; Hendriks, Lizza E.L. Journal: European journal of cancer Issue: Volume 184(2023) Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗